The research was presented today at the IASLC 2024 World Conference on Lung Cancer by Professor Wenhua ... which have been validated against immunohistochemistry results, underscoring the model's ...

BOSTON - Patients with lung nodules often have to undergo several procedures including biopsy and multiple surgeries, but a ...

Targeting EGFR in patients with non-small-cell lung cancer (NSCLC ... with a widely used immunohistochemistry kit. The therapeutic dependence of EGFR modulation on the degree of receptor ...

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...

Datopotamab deruxtecan (Dato-DXd) has been granted Priority Review from the US FDA for advanced EGFR-mutated non-small cell lung cancer (NSCLC) following prior therapies.

T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in ...